Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study.
Identifieur interne : 003F22 ( PubMed/Corpus ); précédent : 003F21; suivant : 003F23Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study.
Auteurs : R V Cluzan ; A P Pecking ; H. Mathiex-Fortunet ; E. Léger PicheritSource :
- Lymphology [ 0024-7766 ] ; 2004.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Aged, 80 and over, Arm (pathology), Breast Neoplasms (drug therapy), Complementary Therapies, Double-Blind Method, Drug Combinations, Female, Humans, Lymphedema (drug therapy), Lymphedema (etiology), Middle Aged, Phytotherapy, Placebos, Plant Extracts (administration & dosage), Plant Extracts (pharmacology), Plant Extracts (therapeutic use), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Plant Extracts.
- chemical , pharmacology : Plant Extracts.
- chemical , therapeutic use : Plant Extracts.
- chemical : Drug Combinations, Placebos.
- drug therapy : Breast Neoplasms, Lymphedema.
- etiology : Lymphedema.
- pathology : Arm.
- Administration, Oral, Adult, Aged, Aged, 80 and over, Complementary Therapies, Double-Blind Method, Female, Humans, Middle Aged, Phytotherapy, Treatment Outcome.
Abstract
The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.
PubMed: 15328756
Links to Exploration step
pubmed:15328756Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study.</title>
<author><name sortKey="Cluzan, R V" sort="Cluzan, R V" uniqKey="Cluzan R" first="R V" last="Cluzan">R V Cluzan</name>
<affiliation><nlm:affiliation>Hospital Cognacq-Jay, Paris, France. malnoue@chello.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A P" last="Pecking">A P Pecking</name>
</author>
<author><name sortKey="Mathiex Fortunet, H" sort="Mathiex Fortunet, H" uniqKey="Mathiex Fortunet H" first="H" last="Mathiex-Fortunet">H. Mathiex-Fortunet</name>
</author>
<author><name sortKey="Leger Picherit, E" sort="Leger Picherit, E" uniqKey="Leger Picherit E" first="E" last="Léger Picherit">E. Léger Picherit</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15328756</idno>
<idno type="pmid">15328756</idno>
<idno type="wicri:Area/PubMed/Corpus">003F22</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003F22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study.</title>
<author><name sortKey="Cluzan, R V" sort="Cluzan, R V" uniqKey="Cluzan R" first="R V" last="Cluzan">R V Cluzan</name>
<affiliation><nlm:affiliation>Hospital Cognacq-Jay, Paris, France. malnoue@chello.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A P" last="Pecking">A P Pecking</name>
</author>
<author><name sortKey="Mathiex Fortunet, H" sort="Mathiex Fortunet, H" uniqKey="Mathiex Fortunet H" first="H" last="Mathiex-Fortunet">H. Mathiex-Fortunet</name>
</author>
<author><name sortKey="Leger Picherit, E" sort="Leger Picherit, E" uniqKey="Leger Picherit E" first="E" last="Léger Picherit">E. Léger Picherit</name>
</author>
</analytic>
<series><title level="j">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Arm (pathology)</term>
<term>Breast Neoplasms (drug therapy)</term>
<term>Complementary Therapies</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphedema (drug therapy)</term>
<term>Lymphedema (etiology)</term>
<term>Middle Aged</term>
<term>Phytotherapy</term>
<term>Placebos</term>
<term>Plant Extracts (administration & dosage)</term>
<term>Plant Extracts (pharmacology)</term>
<term>Plant Extracts (therapeutic use)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Plant Extracts</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Plant Extracts</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Plant Extracts</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term>
<term>Placebos</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Arm</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Complementary Therapies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Phytotherapy</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15328756</PMID>
<DateCreated><Year>2004</Year>
<Month>08</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted><Year>2004</Year>
<Month>10</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-7766</ISSN>
<JournalIssue CitedMedium="Print"><Volume>37</Volume>
<Issue>2</Issue>
<PubDate><Year>2004</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Lymphology</Title>
<ISOAbbreviation>Lymphology</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study.</ArticleTitle>
<Pagination><MedlinePgn>47-52</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cluzan</LastName>
<ForeName>R V</ForeName>
<Initials>RV</Initials>
<AffiliationInfo><Affiliation>Hospital Cognacq-Jay, Paris, France. malnoue@chello.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pecking</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mathiex-Fortunet</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Léger Picherit</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Lymphology</MedlineTA>
<NlmUniqueID>0155112</NlmUniqueID>
<ISSNLinking>0024-7766</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C433389">ginkor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lymphology. 2004 Jun;37(2):43-4</RefSource>
<PMID Version="1">15328754</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000529" MajorTopicYN="Y">Complementary Therapies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008517" MajorTopicYN="Y">Phytotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>10</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>8</Month>
<Day>27</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15328756</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003F22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:15328756 |texte= Efficacy of BN165 (Ginkor Fort) in breast cancer related upper limb lymphedema: a preliminary study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15328756" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |